Management of Locoregional Melanoma

Standard use of adjuvant immunotherapy has significantly improved clinical outcomes in melanoma. Neoadjuvant immunotherapy has further enhanced these benefits in the setting of advanced disease. Lack of a reliable biomarker to monitor treatment response or disease progression has severely limited prognostication accuracy and the individualization of treatment regimens. A reliable biomarker that indicates treatment response or disease progression could guide clinical decision making to benefit patients with high-risk features or significant disease burden by enhanced activation of the innate antitumor immune response or altered gene expression are areas of active investigation to further improve clinical management of melanoma.